XORTX Therapeutics Inc
XTSX:XRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
XORTX Therapeutics Inc
Net Change in Cash
XORTX Therapeutics Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XORTX Therapeutics Inc
XTSX:XRTX
|
Net Change in Cash
-$1.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Change in Cash
$124m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Net Change in Cash
CA$209.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
34%
|
|
|
Cronos Group Inc
TSX:CRON
|
Net Change in Cash
-$67m
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Net Change in Cash
-$275.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Change in Cash
-CA$3.7m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
22%
|
|
XORTX Therapeutics Inc
Glance View
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
See Also
What is XORTX Therapeutics Inc's Net Change in Cash?
Net Change in Cash
-1.6m
USD
Based on the financial report for Dec 31, 2025, XORTX Therapeutics Inc's Net Change in Cash amounts to -1.6m USD.
What is XORTX Therapeutics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
29%
Over the last year, the Net Change in Cash growth was -65%. The average annual Net Change in Cash growth rates for XORTX Therapeutics Inc have been 29% over the past three years .
